Cargando…

P990: NF-ΚB AND JAK/STAT PATHWAYS INHIBITION REVERSES FIBROSIS IN A MURINE MODEL OF INFLAMMATION-DRIVEN MYELOFIBROSIS

Detalles Bibliográficos
Autores principales:	Zamora, Ernesto José Cuenca, Carrillo, Pedro Jesús Guijarro, Poveda, María José López, Fernández, María Luz Morales, Lozano, Maria L, González-Conejero, Rocío, Martínez, Constantino, Teruel Montoya, Raúl, Ferrer-Marín, Francisca
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2023
Materias:	Posters
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10431470/ http://dx.doi.org/10.1097/01.HS9.0000970864.36219.65

Ejemplares similares

P987: IRAK1 AND JAK2 DUAL INHIBITION WITH PACRITINIB PREVENTS MYELOFIBROSIS-LIKE PHENOTYPE IN AN INFLAMMATION-DRIVEN MURINE MODEL
por: Zamora, Ernesto José Cuenca, et al.
Publicado: (2023)

Emerging Role of Neutrophils in the Thrombosis of Chronic Myeloproliferative Neoplasms
por: Ferrer-Marín, Francisca, et al.
Publicado: (2021)

Tubulin in Platelets: When the Shape Matters
por: Cuenca-Zamora, Ernesto José, et al.
Publicado: (2019)

Correction: Cuenca-Zamora, Ernesto José., et al. Tubulin in Platelets: When the Shape Matter. Int. J. Mol. Sci. 2019, 20, 3484
por: Cuenca-Zamora, Ernesto José, et al.
Publicado: (2020)

HSP27 is a partner of JAK2-STAT5 and a potential therapeutic target in myelofibrosis
por: Sevin, Margaux, et al.
Publicado: (2018)

Treatment and management of myelofibrosis in the era of JAK inhibitors
por: Keohane, Clodagh, et al.
Publicado: (2013)

Leukemic transformation driven by an ASXL1 mutation after a JAK2V617F-positive primary myelofibrosis: clonal evolution and hierarchy revealed by next-generation sequencing
por: Ferrer-Marín, Francisca, et al.
Publicado: (2013)

Treatment and management of myelofibrosis in the era of JAK inhibitors [Corrigendum]
Publicado: (2013)

JAK Inhibition for the Treatment of Myelofibrosis: Limitations and Future Perspectives
por: Bose, Prithviraj, et al.
Publicado: (2020)

Myelofibrosis in 2019: moving beyond JAK2 inhibition
por: Schieber, Michael, et al.
Publicado: (2019)

Safety and efficacy of CYT387, a JAK1 and JAK2 inhibitor, in myelofibrosis
por: Pardanani, A, et al.
Publicado: (2013)

Machine Learning Improves Risk Stratification in Myelofibrosis: An Analysis of the Spanish Registry of Myelofibrosis
por: Mosquera-Orgueira, Adrián, et al.
Publicado: (2022)

Coerción, capital y los Estados europeos, 990-1990 /
por: Tilly, Charles
Publicado: (1992)

Electromagnetic characterization of the 990 ton gapless magnets for the OPERA experiment
por: Cazes, A, et al.
Publicado: (2007)

Cytogenetics, JAK2 and MPL mutations in polycythemia vera, primary myelofibrosis and essential thrombocythemia
por: dos Santos, Leonardo Caires, et al.
Publicado: (2011)

Impact of Individual Comorbidities on Survival of Patients with Myelofibrosis
por: García-Fortes, María, et al.
Publicado: (2022)

Will JAK1/2 inhibitors change the standard of care for myelofibrosis?
por: Jung, Chul Won
Publicado: (2012)

Cutaneous cryptococcosis in a patient with myelofibrosis receiving JAK‐inhibitor
por: Chen, Jui‐Che, et al.
Publicado: (2021)

Qualitative and Quantitative Comparison of Plasma Exosomes from Neonates and Adults
por: Peñas-Martínez, Julia, et al.
Publicado: (2021)

The Amelioration of Myelofibrosis with Thrombocytopenia by a JAK1/2 Inhibitor, Ruxolitinib, in a Post-polycythemia Vera Myelofibrosis Patient with a JAK2 Exon 12 Mutation
por: Ikeda, Kazuhiko, et al.
Publicado: (2017)

Accumulation of JAK activation loop phosphorylation is linked to type I JAK inhibitor withdrawal syndrome in myelofibrosis
por: Tvorogov, Denis, et al.
Publicado: (2018)

Finding a Jill for JAK: Assessing Past, Present, and Future JAK Inhibitor Combination Approaches in Myelofibrosis
por: Kuykendall, Andrew T., et al.
Publicado: (2020)

JAK/STAT and Hox Dynamic Interactions in an Organogenetic Gene Cascade
por: Pinto, Pedro B., et al.
Publicado: (2015)

Germline-somatic JAK2 interactions are associated with clonal expansion in myelofibrosis
por: Brown, Derek W., et al.
Publicado: (2022)

The clinical dilemma of JAK inhibitor failure in myelofibrosis: Predictive characteristics and outcomes
por: Mascarenhas, John O., et al.
Publicado: (2022)

JAKs and STATs in chemoresistance
por: Costa-Pereira, Ana P
Publicado: (2010)

JAK-STAT and feeding
por: Ladyman, Sharon R., et al.
Publicado: (2013)

MiRNA-Based Regulation of Hemostatic Factors through Hepatic Nuclear Factor-4 Alpha
por: Salloum-Asfar, Salam, et al.
Publicado: (2016)

990. Prophylaxis against spontaneous bacterial peritonitis: too much or too little?
por: Dhanani, Muhammad, et al.
Publicado: (2020)

Spatial distribution of supratentorial diffuse gliomas: A retrospective study of 990 cases
por: Li, Gen, et al.
Publicado: (2023)

Philadelphia chromosome positive AML arising from JAK2-positive myelofibrosis
por: Brattås, Marte Karen, et al.
Publicado: (2018)

The role of circulating monocytes and JAK inhibition in the infectious-driven inflammatory response of myelofibrosis
por: Barone, Martina, et al.
Publicado: (2020)

Development of JAK2 positive myelofibrosis on a background of chronic myeloid leukaemia
por: Mullen, Christopher Gerard, et al.
Publicado: (2022)

Energy expenditure in myelofibrosis patients treated with a JAK1/2 inhibitor
por: Tremblay, Douglas, et al.
Publicado: (2023)

Changes in patterns of uveitis at a tertiary referral center in Northern Italy: analysis of 990 consecutive cases
por: Luca, Cimino, et al.
Publicado: (2017)

Minerals and Trace Elements in 990 Beverages and Their Contribution to Dietary Reference Values for German Consumers
por: Schaffer, Sebastian, et al.
Publicado: (2022)

The Use of JAK/STAT Inhibitors in Chronic Inflammatory Disorders
por: Caiazzo, Giuseppina, et al.
Publicado: (2023)

A JAK/STAT invasion
por: Wells, William A.
Publicado: (2002)

JAK-STAT and bone metabolism
por: Li, Jiliang
Publicado: (2013)

The Drosophila JAK-STAT pathway
por: Zeidler, Martin P, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_f620qae03ksrjqkbaqhlqjqqgv